SCHEMBL7628550

SCHEMBL7628550

COc1ccc(-n2cn[nH]c2=S)cc1C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.56
PKM P14618 1/20 0.56
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
TDP1 Q9NUW8 1/20 0.43
GFER P55789 1/20 0.40
KDM4E B2RXH2 2/20 0.38
HPGD P15428 2/20 0.38
SIK1 P57059 1/20 0.38
SIK2 Q9H0K1 1/20 0.38
SIK3 Q9Y2K2 1/20 0.38
MYC P01106 1/20 0.38
PTGS1 P23219 1/20 0.38
PTGS2 P35354 1/20 0.38
CYP4F2 P78329 1/20 0.38
CYP4A11 Q02928 1/20 0.38
POLB P06746 1/20 0.37
LCK P06239 1/20 0.37
FYN P06241 1/20 0.37
MAPK1 P28482 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7622774 0.89 ALDH1A1 (0.54) ALDH1A1PKMMEN1KMT2ATDP1
SCHEMBL7621204 0.71 ALDH1A1 (0.47) ALDH1A1KMT2AKDM4EHPGDPOLB
SCHEMBL28328775 0.70 ALDH1A1 (0.49) ALDH1A1KDM4EHPGDMYCPTGS1
SCHEMBL7621451 0.70 TUBB4A (0.40) ALDH1A1KMT2AKDM4EHPGDSIK1
SCHEMBL5806043 0.69 CYP11B1 (0.52) ALDH1A1MEN1KMT2AKDM4EPOLB
SCHEMBL6425207 0.69 KMT2A (0.52) ALDH1A1PKMMEN1KMT2AHPGD
SCHEMBL5323825 0.69 ALDH1A1 (0.57) ALDH1A1TDP1KDM4EHPGDMYC
SCHEMBL12636153 0.67 MEN1 (0.54) ALDH1A1MEN1KMT2AKDM4EHPGD
SCHEMBL234409 0.67 MAP3K5 (0.43)
SCHEMBL5382261 0.66 TDP1 (0.50) ALDH1A1PKMMEN1KMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6423704-B2 CROHN'S DISEAS, ANTIULCER AGENTS, ASTHMA, EMESIS AVENTIS PHARMACEUTICALS INC. 2002-07-23 US disclosed
US-20010034343-A1 Novel substituted 4-(1H-benzimidazol-2-yl) [1,4]diazepanes useful for the treatment of allergic diseases AVENTIS PHARMACEUTICALS INC. 2001-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010034343-A1 Novel substituted 4-(1H-benzimidazol-2-yl) [1,4]diazepanes useful for the treatment of allergic diseases HRH4, HRH2, HRH1 ALDH1A1 953/4885PKM 2920/4885MEN1 1955/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.